CA
NZ
UK
AU
IND
US
● BioNTech rose firmly on Friday, trading at about $92.44 in the afternoon, with no new company announcement.
● Bolt Biotherapeutics climbed strongly on Friday, closing around $4.34, with no announcement from the company.
Alignment Healthcare (NASDAQ:ALHC) shares closed sharply lower after the company's 2027 Centers forMedicareand Medicaid Services Star Ratings showed its largest California contract falling to 3.5 stars from 4.0, threatening eligibility for 2028 quality bonus payments. Alignment Healthcare is a technology-driven, consumer-centric Medicare Advantage insurer …
Arcutis Biotherapeutics (NASDAQ:ARQT) shares traded sharply higher after the company presented new data on its ZORYVEFranchiseat the EADV Congress and the Fall Clinical Dermatology Conference. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for immune-mediated dermatological diseases, with …
Astrana Health (NASDAQ:ASTH) shares closed higher, recovering from Thursday's 3.4% slide as healthcare stocks gained broadly, with the sector ETF up about 1.6% in afternoon trading. Astrana Health is a physician-centric, technology-enabled healthcare management company that operates an integrated, value-based care model across three …
Azenta (NASDAQ:AZTA) shares closed higher, rebounding alongside a broadly firmer healthcare sector even as the company continues to navigate a governance overhang and an ongoing restructuring. Azenta is a global life sciences company that provides solutions for the storage, management, and analysis of biological …
Brookdale Senior Living (NYSE:BKD) shares closed sharply lower after RBC said the company's September occupancy update showed cooling momentum. Brookdale Senior Living is the largest operator of senior living communities in the United States, operating independent living, assisted living, memory care, and continuing care …
Caris Life Sciences (NASDAQ:CAI) shares closed sharply higher after BofA Securities raised its price target on the stock to $35 from $23, a notable move above both the $26.50 consensus target and the $27.08 average analyst target. Caris Life Sciences is an AI-driven precision …
Definium Therapeutics (NASDAQ:DFTX), formerly known as Mind Medicine, shares advanced after JPMorgan initiated coverage on the stock with an Overweight rating and an $84 price target, implying roughly 145% upside from the prior close. Definium Therapeutics is a late-stage clinical biopharmaceutical company applying scientific …
Hims & Hers Health (NYSE:HIMS) shares closed sharply higher, rallying alongside a broader healthcare sector rebound and recovering a meaningful portion of the prior session's roughly 5% decline. Hims & Hers Health is a digital health platform that connects consumers with licensed medical professionals …
Please wait processing your request...